69 related articles for article (PubMed ID: 32273288)
1. Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study.
Imamura Y; Watanabe M; Oki E; Morita M; Baba H
Ann Gastroenterol Surg; 2021 Jan; 5(1):46-59. PubMed ID: 33532680
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry.
Pérez-Wert P; Custodio A; Jimenez-Fonseca P; Carmona-Bayonas A; Lecumberri A; Cacho Lavin D; Losantos García I; Fernández Montes A; Cano JM; Limón ML; Hernández San Gil R; Diez M; Vidal Tocino R; Macías Declara I; Visa L; Pimentel Cáceres P; Gil Raga M; Martínez Moreno E; Sauri T; Martín Richard M; Granja M; Cerdà P; Gómez González L; Mérida-García A; Ruiz Martín M; Gallego J;
Gastric Cancer; 2024 Jan; 27(1):131-145. PubMed ID: 37964032
[TBL] [Abstract][Full Text] [Related]
3. Adenocarcinoma of the stomach: a review.
McLoughlin JM
Proc (Bayl Univ Med Cent); 2004 Oct; 17(4):391-9. PubMed ID: 16200126
[No Abstract] [Full Text] [Related]
4. Gastric cancer.
Smyth EC; Nilsson M; Grabsch HI; van Grieken NC; Lordick F
Lancet; 2020 Aug; 396(10251):635-648. PubMed ID: 32861308
[TBL] [Abstract][Full Text] [Related]
5. Utilizing artificial intelligence in endoscopy: a clinician's guide.
Namikawa K; Hirasawa T; Yoshio T; Fujisaki J; Ozawa T; Ishihara S; Aoki T; Yamada A; Koike K; Suzuki H; Tada T
Expert Rev Gastroenterol Hepatol; 2020 Aug; 14(8):689-706. PubMed ID: 32500760
[TBL] [Abstract][Full Text] [Related]
6.
Nakayama I; Hirota T; Shinozaki E
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33152998
[TBL] [Abstract][Full Text] [Related]
7. Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023.
Kitagawa Y; Matsuda S; Gotoda T; Kato K; Wijnhoven B; Lordick F; Bhandari P; Kawakubo H; Kodera Y; Terashima M; Muro K; Takeuchi H; Mansfield PF; Kurokawa Y; So J; Mönig SP; Shitara K; Rha SY; Janjigian Y; Takahari D; Chau I; Sharma P; Ji J; de Manzoni G; Nilsson M; Kassab P; Hofstetter WL; Smyth EC; Lorenzen S; Doki Y; Law S; Oh DY; Ho KY; Koike T; Shen L; van Hillegersberg R; Kawakami H; Xu RH; Wainberg Z; Yahagi N; Lee YY; Singh R; Ryu MH; Ishihara R; Xiao Z; Kusano C; Grabsch HI; Hara H; Mukaisho KI; Makino T; Kanda M; Booka E; Suzuki S; Hatta W; Kato M; Maekawa A; Kawazoe A; Yamamoto S; Nakayama I; Narita Y; Yang HK; Yoshida M; Sano T
Gastric Cancer; 2024 May; 27(3):401-425. PubMed ID: 38386238
[No Abstract] [Full Text] [Related]
8. Systemic chemotherapy for gastro-oesophagogastric junction adenocarcinoma and stomach adenocarcinoma in a metastatic setting.
Sanjeevaiah A; McGehee E
ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32646964
[No Abstract] [Full Text] [Related]
9. Advances in the treatment of gastric cancer.
Ilson DH
Curr Opin Gastroenterol; 2020 Nov; 36(6):525-529. PubMed ID: 32889823
[TBL] [Abstract][Full Text] [Related]
10. Considering the esophagogastric junction as a 'zone'.
Ichihara S; Uedo N; Gotoda T
Dig Endosc; 2017 Apr; 29 Suppl 2():3-10. PubMed ID: 28425656
[TBL] [Abstract][Full Text] [Related]
11. Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting.
Nakayama I; Takahari D; Wakatsuki T; Osumi H; Chin K; Ogura M; Sato T; Suzuki T; Kamiimabeppu D; Ooki A; Suenaga M; Shinozaki E; Yamaguchi K
ESMO Open; 2020 Apr; 5(2):. PubMed ID: 32273288
[TBL] [Abstract][Full Text] [Related]
12. CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.
Schmalenberg H; Al-Batran SE; Pauligk C; Zander T; Reichart A; Lindig U; Kleiß M; Müller L; Bolling C; Seufferlein T; Reichardt P; Kullmann F; Eschenburg H; Schmittel A; Egger M; Block A; Goetze TO
J Cancer Res Clin Oncol; 2018 Mar; 144(3):559-569. PubMed ID: 29285668
[TBL] [Abstract][Full Text] [Related]
13. Primary Tumor Location Is a Predictor of Poor Prognosis in Patients with Locally Advanced Esophagogastric Cancer Treated with Perioperative Chemotherapy.
Felismino TC; de Oliveira ACF; Alves ACF; da Costa Junior WL; Coimbra FJF; de Souza Begnami MDF; Riechelmann RP; de Jesus VHF; de Mello CAL
J Gastrointest Cancer; 2020 Jun; 51(2):484-490. PubMed ID: 31179509
[TBL] [Abstract][Full Text] [Related]
14. Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma.
Tokunaga R; Imamura Y; Nakamura K; Uchihara T; Ishimoto T; Nakagawa S; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Oyama S; Shono T; Naoe H; Saeki H; Oki E; Watanabe M; Sasaki Y; Maehara Y; Baba H
Cancer Med; 2015 Nov; 4(11):1659-66. PubMed ID: 26310928
[TBL] [Abstract][Full Text] [Related]
15. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
Lorenzen S; Thuss-Patience P; Al-Batran SE; Lordick F; Haller B; Schuster T; Pauligk C; Luley K; Bichev D; Schumacher G; Homann N
Ann Oncol; 2013 Aug; 24(8):2068-73. PubMed ID: 23592699
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
